Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 15/20 | 0.73 |
| ▸ | JAK2 | O60674 | 7/20 | 0.59 |
| ▸ | PLK4 | O00444 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17660755 | 0.89 | TBK1 (0.76) | TBK1JAK2 | |
| SCHEMBL17630756 | 0.85 | TBK1 (1.00) | TBK1JAK2 | |
| SCHEMBL17660796 | 0.82 | TBK1 (0.76) | TBK1JAK2 | |
| SCHEMBL17660789 | 0.80 | TBK1 (0.77) | TBK1JAK2MAPK10KDR | |
| SCHEMBL17660756 | 0.80 | TBK1 (0.73) | TBK1JAK2 | |
| SCHEMBL17661037 | 0.79 | TBK1 (0.77) | TBK1JAK2 | |
| SCHEMBL17660824 | 0.78 | TBK1 (0.78) | TBK1JAK2 | |
| SCHEMBL17661040 | 0.78 | TBK1 (0.79) | TBK1JAK2PLK4KDR | |
| SCHEMBL17660771 | 0.78 | JAK2 (0.79) | TBK1JAK2 | |
| SCHEMBL17660782 | 0.78 | TBK1 (0.79) | TBK1JAK2PLK4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10040781-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20160096827-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10040781-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | TBK1 4/4885JAK2 750/4885PLK4 476/4885 |
| US-20160096827-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | TBK1 4/4885JAK2 750/4885PLK4 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.